Gemphire Therapeutics Inc. (GEMP) Trading at $10.11 after Rise on Jun, 29

June 29, 2018 - By Ashley Bratcher

Gemphire Therapeutics Inc. (NASDAQ:GEMP) trading at $10.11 after increase. The move was reported on Jun, 29 by Barchart.com. The company has $143.89M market cap. At $10.72 PT, the company’s valuation could be $8.63 million more.

On August, 13 is anticipated Gemphire Therapeutics Inc. (NASDAQ:GEMP)’s earnings report, Zacks reports. Analysts expect change of 22.97 % or $0.17 from previous year’s $-0.74 EPS compared to current’s $-0.57 EPS. Wall Street sees -1.72 % EPS growth as of August, 13.

For more Gemphire Therapeutics Inc. (NASDAQ:GEMP) news brought out briefly go to: Benzinga.com, Streetinsider.com, Benzinga.com, Benzinga.com or Streetinsider.com. The titles are as follows: “Benzinga Pro’s 5 Stocks To Watch Today” brought out on June 29, 2018, “After-Hours Stock Movers 06/28: (GEMP) (NKE) (VRTX) Higher; (SNX) (CVG) Lower (more…)” on June 28, 2018, “5 Stocks Moving In Thursday’s After-Hours Session” with a publish date: June 21, 2018, “Benzinga’s Daily Biotech Pulse: Gemphire On Fire, Acceleron-Celgene Taste Success, AbbVie Ditches Galapagos” and the last “Pre-Open Movers 06/29: (GEMP) (DERM) (NKE) Higher; (PFIE) (STZ) (SNX) Lower (more…)” with publication date: June 29, 2018.

Gemphire Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of dyslipidemia cardiovascular disease and nonalcoholic fatty liver disease/non-alcoholic steatohepatitis .The company has $143.89 million market cap. It is developing gemcabene (CI-1027), an oral therapy for patients who are unable to achieve normal levels of LDL-C or triglycerides with currently approved therapies, primarily statin therapy and for those patients who present with NASH.Currently it has negative earnings.

Gemphire Therapeutics Inc. (NASDAQ:GEMP) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.